Promega Corporation and Watchmaker Genomics have formed a strategic partnership, with Promega licensing a new, engineered reverse transcriptase enzyme from Watchmaker. This collaboration is set to enhance Promega’s ability to provide high-quality, customized solutions for a variety of molecular applications, including clinical diagnostics, applied sciences, and pharmaceutical research. According to Sara Mann, Vice President of Commercial Excellence at Promega, this enzyme establishes a new benchmark for reverse transcriptase performance due to its unique combination of attributes. The licensing of this technology gives Promega's customers a more powerful tool for improving the accuracy and sensitivity of their RNA-based assays.

have formed a strategic partnership, with Promega licensing a new, engineered reverse transcriptase enzyme from Watchmaker. This collaboration is set to enhance Promega’s ability to provide high-quality, customized solutions for a variety of molecular applications, including clinical diagnostics, applied sciences, and pharmaceutical research. According to Sara Mann, Vice President of Commercial Excellence at Promega, this enzyme establishes a new benchmark for reverse transcriptase performance due to its unique combination of attributes. The licensing of this technology gives Promega's customers a more powerful tool for improving the accuracy and sensitivity of their RNA-based assays.

have formed a strategic partnership, with Promega licensing a new, engineered reverse transcriptase enzyme from Watchmaker. This collaboration is set to enhance Promega’s ability to provide high-quality, customized solutions for a variety of molecular applications, including clinical diagnostics, applied sciences, and pharmaceutical research. According to Sara Mann, Vice President of Commercial Excellence at Promega, this enzyme establishes a new benchmark for reverse transcriptase performance due to its unique combination of attributes. The licensing of this technology gives Promega's customers a more powerful tool for improving the accuracy and sensitivity of their RNA-based assays.

The reverse transcriptase was developed using Watchmaker’s proprietary protein engineering platform. It is designed to offer significant advantages for molecular analysis, including enhanced thermostability for efficient cDNA synthesis at elevated temperatures, exceptional inhibitor tolerance for handling challenging samples, and improved processivity to boost the sensitivity for low-abundance targets. These features are critical for modern diagnostic and research labs that require high levels of accuracy and reliability in their RNA analysis.

This initial partnership is just the beginning of a broader collaboration between the two companies. Both Promega and Watchmaker are committed to developing next-generation enzyme technologies to meet the evolving needs of the life science and molecular diagnostics fields. The agreement expands Promega's nucleic acid analysis portfolio with a reverse transcriptase that provides the sensitivity, robustness, and reproducibility necessary for today's most demanding applications in clinical, applied, and biotech markets. This collaboration highlights the power of Watchmaker's enzyme engineering platform and positions Promega to offer an even more robust portfolio of products to its global customer base.